BRAF and neoplasm: In 2021, Jung et al. established novel canine TCC cell lines from two tumour tissues and one metastatic lymph node from canine patients with BRAF-mutated TCC and compared the effect of sorafenib and vemurafenib on these three canine cell lines and one human BRAF-mutated TCC cell line.